Replimune Just Doubled After a 10-3 Vote — That's Not the Story. The Story Is That Two FDA Rejections Just Became One Approval

On the evening of July 30, 2026, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 10-3 that efficacy results from Replimune Group's pivotal IGNYTE study were 'evaluable and clinically meaningful' for RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1-failed advanced melanoma. The PDUFA date is August 2, 2026 — three calendar days after the vote. Within hours, Replimune Group shares jumped roughly 128% premarket to $12.44, more than recouping the 38% they gave up the prior Tuesday after FDA briefing documents flagged the same dataset as 'messy.'

RP1's path to the July 30 adcom is the most-bifurcated regulatory story in small-cap biotech. The original BLA was filed in November 2024, accepted with Priority Review in January 2025, and rejected via Complete Response Letter (CRL) on July 21, 2025 — the FDA's view was that IGNYTE was not an adequate and well-controlled study. A first resubmission was accepted in October 2025 with a new PDUFA date of April 10, 2026. The FDA delivered a second CRL on that exact date, citing the same trial-design concerns: no randomized comparator, inability to separate nivolumab's contribution from RP1's, and 49% of responders having all injected target lesions (no noninjected lesions to assess systemic effect).

Then the FDA itself changed. Vinay Prasad, who had led CBER through both rejections, departed on April 30, 2026. Marty Makary stepped down as Commissioner on May 12, 2026. By May 29, 2026, Replimune announced it would resubmit a third time — the resubmission was accepted as Class 1 on June 26, 2026, with the August 2 PDUFA date the panel vote is now positioned to defend.

The IGNYTE trial enrolled 140 anti-PD-1-failed advanced melanoma patients, running RP1+nivolumab in a single-arm Phase 1/2. The confirmed objective response rate was 32.9% by RECIST v1.1 (33.6% by modified RECIST), with a 15.0% complete response rate and a median duration of response of roughly 35 months. The 3-year landmark overall survival (OS) analysis — published via Replimune IR and ASCO 2026 — showed median OS of 32.9 months and 1-/2-/3-year OS rates of 75.3%, 61.5%, and 47.8%.

FDA staff had argued the ORR and DoR were 'unreliable and difficult to interpret' because 49% of responders had only injected lesions — meaning you could not show that RP1 was doing anything beyond what nivolumab alone does. The panel disagreed, voting 10-3 that the data were 'evaluable and clinically meaningful' even with that limitation. The decisive factor for the panel was the responder vs. non-responder OS split: median OS was not reached in patients who responded versus 18.5 months in non-responders, plus the durability signal (33.7-month median DOR) in a population with effectively no remaining standard-of-care options.

The addressable population is anti-PD-1-failed advanced melanoma — patients who have already progressed on Keytruda or Yervoy+Opdivo combinations. That is a small but real slice: roughly 8,000-10,000 US patients per year who exhaust front-line PD-1 blockade and have limited third-line options. Replimune retains full commercial rights to RP1 — Bristol-Myers Squibb supplies nivolumab at no cost under a 2018 Clinical Trial Collaboration and Supply Agreement, and the deal is royalty-free, non-exclusive, with no milestones owed back to Bristol-Myers Squibb.

The competitive reality favors Interception: Iovance's Amtagvi already serves PD-1-failed melanoma with a 31% ORR, but it requires a tumor biopsy, ex vivo expansion, and lymphodepletion — a roughly $500K+ course of therapy. RP1 is an off-the-shelf intratumoral injection paired with an approved checkpoint inhibitor. Both compete for the same patient, but the friction comparison drives the on-label narrative.

Replimune Group reported $268.9M in cash and short-term investments as of March 31, 2026, down from $483.8M a year earlier. FY26 (fiscal year ending March 2026) operating expenses were $319.9M, producing a net loss of $313.9M, or $3.38 per share on 92.8M weighted-average shares. Q3 FY26 R&D alone was $53.1M. Annualizing the FY26 burn implies a cash runway of roughly 10-12 months at current spend — comfortably enough to clear the August 2 PDUFA and the confirmatory IGNYTE-3 readout, but not enough to fund a full commercial launch without a raise or a partnership.

The phrase 'Regulated by the FDA' has been a binary risk for small-cap biotech all year. The SPDR S&P Biotech ETF (XBI) was down 49% at one point over the trailing cycle, and the industry consensus was that any single-arm oncology asset targeting accelerated approval carried a ~70% probability of rejection. The Replimune vote — paired with the Capricor loss — falsifies that uniform-downside framing. The FDA under acting Commissioner Kyle Diamantas (in seat since May 15, 2026) is sending panels back to the data, not to ideology.

That matters because the prior leadership — Prasad at CBER, Makary at the top — had been visibly skeptical of single-arm accelerated approval. With both gone, the question is no longer 'will the FDA block this on priors?' but 'does the data clear the bar?' Replimune Group's data cleared it. Capricor's Duchenne Phase 3 surrogate-endpoint data did not. Investors who assumed all 2026 adcom outcomes were skewed negative now have a recent counterexample to anchor against.

The August 2 PDUFA is the only binary catalyst that matters for Replimune Group in the next week. A 10-3 panel vote in favor typically pulls the FDA's hand toward approval, but the agency's track record on voting-against-adcom-opinion approvals has been mixed. The most likely paths: approval (probability ~65-70% based on the panel's view of clinical meaningfulness), Complete Response with a request for more data (probability ~20-25%), or outright rejection (~10%). The CR path would retrigger the downside-skew narrative; the approval path would lock in the upside.

The 10-3 vote does three things at once. It gives Replimune Group a fighting chance at an approval within 72 hours. It confirms that an FDA panel — under the same leadership structure that just rejected Capricor — can still vote 'yes' on a single-arm oncology asset when the survival signal is real. And it pulls forward a calendar event most biotech bears had not expected until 2027: the first concrete data point that the post-Prasad, post-Makary FDA is empirically more willing to approve, not just more willing to convene.

That last point is the one that matters for portfolio construction. Through 2025 and the first half of 2026, the assumption priced into small-cap biotech was that any single-arm BLA required not only great data but also a sympathetic reviewer. With the friendly reviewers gone, the bar actually got higher — and Replimune Group cleared it anyway. The market is now repricing what an Approval Probability Normal looks like, and the immediate bar is whether the FDA confirms the panel's view on Saturday.